AstraZeneca Fails to Prove the Drug Selumetinib for Thyroid cancer
Shots:
- The drug failed to meet the primary endpoint of thyroid cancer lead to its failure as well as removal from phase 3- double blind involved in high risk DTC
- The licensor AstraZeneca refused to pay royalties to the license Array pharma for the drug
- AstraZeneca to pay $192million according to licensing deal to Array Pharm
Ref: Array Biopharma | Image: AstraZeneca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com